SANDY, Utah--(BUSINESS WIRE)--Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that they have strengthened relationships with key regional customers throughout the Caribbean basin to purchase the Company’s Zika virus diagnostic.
The potential customer base includes laboratories, regional health ministries, and hospitals interested in offering a state-of-the-art molecular diagnostic for the Zika virus to their customers, citizens, and patients. To date, Company representatives and future product distributors have conducted on-site suitability assessments at dozens of locations in countries across the region, with the understanding that these locations would be among the first to have access to the Zika virus test upon completion of successful performance evaluation and validation studies. The Company is also an approved reseller of diagnostic equipment, to enable upgraded laboratory facilities for those locations who have not previously been able to offer molecular diagnostics.
Dwight Egan, Co-Diagnostics CEO, remarked, “Molecular diagnostics are the internationally recognized gold standard in disease detection, and Co-Diagnostics’ assays are built on our own platform without expensive royalty payments built in to the cost. We are uniquely positioned to assist the many overlooked and underserved populations in this region interested in a competitively priced, high quality diagnostic tool to assist in the detection of the Zika virus.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that has developed and
intends to manufacture and sell reagents used for diagnostic tests that
function via the detection and/or analysis of nucleic acid molecules
(DNA or RNA), and to sell diagnostic equipment from other manufacturers
as self-contained lab systems.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be identified
by words such as "believes," "expects," "estimates," "intends," "may,"
"plans," "will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as to
future facts and conditions. Readers of this press release are cautioned
not to place undue reliance on any forward-looking statements. The
Company does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release, except as
may be required by applicable securities laws.
Disclaimer:
This news release does not constitute an offer
to sell or a solicitation of an offer to buy the securities described
herein, nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.